Pediapax Powder 400 g

Pediapax is a product used for the treatment of chronic constipation, supporting bowel movement in children. Pediapax powder is a product that is:
  • Gluten-free and lactose-free
  • Hydrates the stool
  • Allows painless passing of stools
Pediapax for children is also indicated for faecal impaction in children from 3 years of age, for any constipated child.
In stock, ready to ship
935543470
€15.22
Tax included

  • Express delivery: in 24/48 hours
    Standard in 3-5 working days
  • Shipping
    Standard €6.50, express €9.00
    Sardinia, Venice and minor islands: €20.00
  • Returns within 14 days
    Right of withdrawal guaranteed
  • Secure payments
    Visa, Mastercard, American Express, PayPal, PayPal in 3 rate, Google Pay, Klarna, Bonifico

Need help? Contact us

Description

Pediapax

MACROGOL 3350
pure, electrolyte-free, flavour-free, excipient-free


Gluten-Free

Useful for the treatment of constipation
and faecal impaction in children


For more targeted dosage management
Ideal in the initial and final phases of chronic constipation therapy


Dosage recommended by the
ESPGHAN/NASPGHAN 2014 Guidelines: 0.2-0.8 g/kg/day


One teaspoon = 5 g of macrogol to be dissolved
in half a glass of still water


• The dose can be increased or decreased
according to individual response.

1. IDENTIFICATION, COMPOSITION AND INTENDED USE OF THE MEDICAL DEVICE
1.1 Description and indications for use
Pediapax is a medical device in powder form for extemporaneous oral suspension, useful in the:
• treatment of chronic constipation in children over 2 years of age weighing 10 kg or more.
• treatment of faecal impaction in children from 3 years of age, defined as refractory constipation with faecal loading in the rectum and/or colon.
1.2 Composition
Each bottle contains 400 g of Macrogol 3350. Pediapax does not contain gluten.
1.3 Shelf life
36 months.
1.4 Mechanism of action
The efficacy of the device is due to the characteristics of polyethylene glycol (PEG), a high molecular weight, metabolically inert polymer that is not degraded by the intestinal bacterial flora; water molecules are retained on the long linear polymer chains by hydrogen bonds, hydrating the stool and stimulating peristalsis. Pediapax is not absorbed in the intestine and is excreted unchanged.

2. DIRECTIONS FOR USE
2.1 Chronic constipation
Unless otherwise prescribed by a doctor, Pediapax should be used as follows.

Weight (kg)Maximum recommended
daily dose
10-12 kg2 teaspoons
13-20 kg 2 ½ teaspoons
21-25 kg 3 teaspoons
26-30 kg 4 teaspoons
> 30 kg 5 teaspoons

The dose can be increased or decreased according to the individual response to treatment. The most appropriate daily dosage should be decided according to the child's weight and the severity of the constipation.
In any case, seek your doctor's advice.
Use the product in children only on medical advice.
The maximum dose required does not normally exceed 30 g of product per day.
According to the dosage above, measure the amount of product using the measuring scoop, which has marks for 2.5 g (first mark) and 5 g (level scoop) of product.
Dissolve one level scoop (5 g) in 62.5 ml of still water (about ½ glass).
The daily dose can be divided into several administrations.
2.2 Faecal impaction
The diagnosis of faecal impaction/faecal loading in the rectum must be confirmed by physical or radiological examination of the abdomen and rectum.
The dosage recommended by the ESPGHAN and NASPGHAN guidelines is 1-1.5 g per kg of body weight per day.
The dosage for the treatment of faecal impaction with Pediapax is therefore as follows:
Weight (kg)Maximum recommended daily dose
14-17 kg4 teaspoons
18-22 kg 5 teaspoons
23-27 kg 6 and a half teaspoons
28-34 kg 8 teaspoons
35-39 kg 9 teaspoons
> 40 kg 10 and a half teaspoons

The daily dosage must be taken divided into doses of 5 g (level scoop), each dissolved in about 62.5 ml of water (about half a glass), to be consumed entirely within 12 hours; for correct use of the product, we recommend consulting your doctor. Treatment should be stopped once the impaction has resolved, and in any case should last no more than 6 consecutive days. An indicator of resolution is the passage of a large quantity of stool. After resolution, the child should follow an appropriate bowel treatment programme to prevent a new faecal impaction (the dosage to prevent recurrence of faecal impaction is that for patients with chronic constipation - Ref. § 2.1).
NOTE: a larger volume of ready-to-use solution can be prepared. In this case the solution can be kept covered in the fridge for a maximum of 24 hours, and then discarded.

3. KNOWN SIDE EFFECTS
Especially in the initial phase of use, gastrointestinal disturbances may occur (abdominal pain, borborygmi, diarrhoea or faecal leakage), as well as nausea, mild vomiting, abdominal distension, flatulence, perianal inflammation and irritation; these effects normally improve by reducing the dose. Allergic reactions, including anaphylaxis, have been observed very rarely. Other symptoms of allergic reactions include itching, urticaria and dyspnoea. If side effects persist, stop treatment and consult your paediatrician.

4. STORAGE
Store the intact pack in a dry place away from direct light or heat. Store the device below 25°C.

5. WARNINGS AND PRECAUTIONS
Keep the device and any prepared solution out of the reach of children.
Do not use the device after the expiry date shown on the pack.
Do not use if the pack is damaged.
Never exceed the recommended doses: overdose may cause severe pain and abdominal distension.
Induced diarrhoea may also occur, with electrolyte disturbances caused by excessive evacuation.
If overdose is suspected, contact your paediatrician immediately.
When Pediapax is used in high doses to treat faecal impaction, it should be given with caution to patients with an impaired gag reflex, reflux oesophagitis or reduced levels of consciousness. If you forget to take a dose, DO NOT TAKE A DOUBLE DOSE to make up for it.
During treatment with Pediapax it is advisable to follow a suitable diet, together with an oral rehydration solution (ORS) to avoid dehydration; in any case, consult your doctor.

6. CONTRAINDICATIONS AND LIMITATIONS OF USE
Do not use under 2 years of age for the treatment of chronic constipation or under 3 years for the treatment of faecal impaction. Use of the device is not recommended in cases of: intestinal perforation or obstruction due to structural or functional disorders of the intestinal wall, ileus, severe inflammatory diseases of the intestinal tract such as Crohn's disease, ulcerative colitis and toxic megacolon. Known hypersensitivity to PEG. Do not take the medical device while using other oral devices or medicinal products: the osmotic power of PEG and the induced increase in gastrointestinal transit speed may reduce their efficacy. In any case, consult your doctor before taking Pediapax if you are on other treatments. Do not use in the presence of known gastric or intestinal lesions.

7. INTERACTIONS WITH MEDICINES AND FOOD SUPPLEMENTS
No interactions with medicines are known to date, but the product should be taken at least 2 hours apart from orally administered medicines, as the osmotic power of macrogol and the induced increase in gastrointestinal transit speed may reduce their efficacy. In any case, consult your doctor before taking Pediapax if you are on other treatments.

8. DISPOSAL
Expired devices or devices to be discarded must be handled in accordance with local waste management regulations. Never dispose of the product or its packaging in the environment.

Size
400 g bottle with 5 g measuring spoon with half-dose mark.

Product Details

Format
ORAL POWDER
321 Items

10 other products in the same category:

Product added to wishlist
Product added to compare.